Phacilitate Leaders World

Sponsors & Exhibitors

Scinus Cell Expansion

Scinus Cell Expansion BV (Bilthoven, The Netherlands) is a privately owned company, developing and marketing innovative technologies for cell production. Our mission is to make cell therapies accessible for a global patient population. The core activity of Scinus is the development and marketing of an innovative bioreactor platform technology for the cell culture industry. The Scinus Cell Expansion system offers a cost-effective, controlled alternative to conventional cell production strategies. The patented technology allows cell culture professionals to perform the entire cell expansion process, from biopsy to over 1 billion cells, within one closed system. Therefore, Scinus bioreactor technology is ideal for scale-out of both adherent and suspension cell culture. Scinus Cells Expansion also offers services to assist its clients in the transition to a commercial-scale GMP production strategy for their cell products.

Visit Website
View all Sponsors & Exhibitors
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman